Filing Details

Accession Number:
0000899243-21-009370
Form Type:
4
Zero Holdings:
No
Publication Time:
2021-03-03 16:05:17
Reporting Period:
2021-03-01
Accepted Time:
2021-03-03 16:05:17
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1661998 Homology Medicines Inc. FIXX Pharmaceutical Preparations (2834) 473468154
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1754067 P Timothy Kelly C/O Homology Medicines, Inc.
One Patriots Park
Bedford MA 01730
See Remarks. No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2021-03-01 2,000 $6.63 4,232 No 4 M Direct
Common Stock Acquisiton 2021-03-01 2,000 $2.89 6,232 No 4 M Direct
Common Stock Acquisiton 2021-03-01 6,232 $11.16 0 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Employee Stock Options Disposition 2021-03-01 2,000 $0.00 2,000 $6.63
Common Stock Employee Stock Options Disposition 2021-03-01 2,000 $0.00 2,000 $2.89
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
41,500 2027-12-06 No 4 M Direct
32,001 2027-09-06 No 4 M Direct
Footnotes
  1. Includes 2,232 shares acquired under Issuer's Employee Stock Purchase Plan on February 26, 2021.
  2. The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 3, 2020.
  3. The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $10.9600 to $11.3100. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  4. The option vests and becomes exercisable upon the Reporting Person's completion of each full month of service after January 1, 2018, so that such option will become fully vested on January 1, 2022.
  5. The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in equal monthly installments over a three year period thereafter. The vesting commencement date for this option was May 30, 2017.